Compass Therapeutics

CMPX

Market cap $613M

Overview Fund Activity

3.57 USD

+0.04

1.13%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

3.50

-0.07

1.96%

1 day

1.13%

5 days

4.39%

1 month

12.62%

3 months

48.13%

6 months

42.23%

Year to date

155%

1 year

131.82%

5 years

-10.3%

10 years

-10.3%

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Employees: 35

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

37% more capital invested

Capital invested by funds: $206M [Q1] → $281M (+$75.4M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0.14% less ownership

Funds ownership: 78.42% [Q1] → 78.28% (-0.14%) [Q2]

4% less funds holding

Funds holding: 107 [Q1] → 103 (-4) [Q2]

17% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 24

41% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 41

99% less call options, than puts

Call options by funds: $85K | Put options by funds: $6.54M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

152% upside

Avg. target

$17.67

395% upside

High target

$32

796% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert	$32	Buy Maintained	12 Aug 2025
Guggenheim Michael Schmidt	$12	Buy Maintained	12 Aug 2025
Raymond James Sean McCutcheon	$9	Outperform Reinstated	1 Jul 2025

See Analyst Rankings

Financial journalist opinion

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Compass Therapeutics, Inc. (NASDAQ:CMPX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Thomas Schuetz - CEO & Vice Chairman Barry Shin - Chief Financial Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy Good afternoon, everyone. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and it's great to be here with the management team of Compass Therapeutics.

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September.

Compass Therapeutics to Participate in Upcoming September Investor Events

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC support dose expansion, with detailed phase 1 data expected in Q4 2025. Preclinical candidate CTX-10726 demonstrates potential superiority to competitors, with an IND submission targeted for Q4 2025.

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET.

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat Details Date: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page.

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio.

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting.

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™